1. Home
  2. WLDS vs CVKD Comparison

WLDS vs CVKD Comparison

Compare WLDS & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wearable Devices Ltd.

WLDS

Wearable Devices Ltd.

HOLD

Current Price

$2.41

Market Cap

7.7M

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$3.06

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLDS
CVKD
Founded
2014
2022
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Medicinal Chemicals and Botanical Products
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
6.2M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
WLDS
CVKD
Price
$2.41
$3.06
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
1.4M
36.0K
Earning Date
03-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.54
52 Week High
$11.40
$14.64

Technical Indicators

Market Signals
Indicator
WLDS
CVKD
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
WLDS
CVKD

About WLDS Wearable Devices Ltd.

Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: